Scott Benson, DO
Nephrology · Hartford, CTNPI 1669597639
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 28.7% of the total. Reporting peaked in 2019 at $231 and has fallen 88.1% since, to $27 in 2025.
Across 35 payments — averaging $21.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$219
- Amgen$126
- Covidien LP$100
- Cook Medical LLC$80
- BD$64
- Travere Therapeutics, Inc.$54
- plus $121 from 5 others
What the payments were for
- Food & beverage$75399%
- Education$111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 7 | $219 |
| Amgen | 6 | $126 |
| Covidien LP | 3 | $100 |
| Cook Medical LLC | 2 | $80 |
| BD | 4 | $64 |
| Travere Therapeutics, Inc. | 7 | $54 |
| Lemaitre Vascular, Inc. | 2 | $42 |
| Medtronic | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $20 |
| Nxstage Medical, Inc. | 1 | $17 |
How this compares
$764 in reported general payments places this provider in the 55th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 14 | $37,591 |
| Lanthanum Carbonate | 16 | $23,101 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 78 | $20,781 |
| ProsolParenteral Amino Acid 20% No.1 | 114 | $18,964 |
| Sevelamer Carbonate | 44 | $9,781 |
| Potassium Citrate ErPotassium Citrate | 16 | $2,492 |
| Calcium Acetate | 39 | $1,499 |
| Midodrine Hcl | 31 | $797 |
| Ondansetron Hcl | 11 | $449 |
| Torsemide | 14 | $419 |
| Calcitriol | 19 | $337 |
| Clonidine Hcl | 26 | $204 |
| Carvedilol | 24 | $187 |
| Gabapentin | 22 | $170 |
| Allopurinol | 23 | $113 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hartford
- Xiaoyi YeHartford$25K
- Terrence OderHartford$1K
- Robert AlpernNew Haven$4.9M
- Ari GellerBloomfield$209K
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.